Post Marketing Surveillance Study To Observe Safety And Efficacy Of Ibrance (Registered).

Trial Profile

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Ibrance (Registered).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 May 2018

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Adenocarcinoma; Breast cancer
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 16 May 2018 Planned End Date changed from 28 Apr 2023 to 30 Apr 2022.
    • 16 May 2018 Planned primary completion date changed from 28 Apr 2023 to 30 Apr 2022.
    • 04 Apr 2018 Planned End Date changed from 30 Apr 2022 to 28 Apr 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top